[e-farmacos] Drug Safety Newsletter Update 2008; vol 1, num 2

["Canas, Martin" <farmacol@femeba.org.ar>]

Estimadas y estimados,

Ya salio el FDA Drug Safety Newsletter Volume 1, Number 2  Winter 2008
En este numero:

 Editor's Note
 Postmarketing Reviews
- Exenatide (marketed as BYETTA): Acute Pancreatitis

- PHOSPHODIESTERASE TYPE 5 (PDE5) INHIBITORS
Sildenafil citrate (marketed as VIAGRA and REVATIO), vardenafil
hydrochloride (marketed as LEVITRA), and tadalafil (marketed as CIALIS):
Sudden Hearing Loss

- TUMOR NECROSIS FACTOR ALPHA (TNF-?) ANTAGONISTS
Infliximab (marketed as REMICADE), etanercept (marketed as ENBREL), and
adalimumab (marketed as HUMIRA): Serious Skin Reactions

- New Molecular Entity (NME) - 3 Years Later
Duloxetine (marketed as CYMBALTA)

Feature Article
Pharmacogenomics and Its Role In Drug Safety

Drug Safety Communications

disponible en:
http://www.fda.gov/cder/dsn/2008_winter/2008_winter.pdf

Saludos,

Martin

Martin Canas
GAPURMED
La Plata
(Argentina)
macanas@netverk.com.ar